December 31, 2024 7:58am

Tuesday, the market closes at 4 p.m., the bond at 2 p.m.; markets are closed on Wednesday for New Year’s Day

Pre-open Indications: 8 Positive and 2 Negative Indications

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

Monday’s night’s … RegMed Investors (RMi) Closing Bell: losers for now … https://www.regmedinvestors.com/articles/13749

 

Tuesday; the pre-open Dow futures are UP +0.25% or (+108 points), the S&P futures are UP +0.31% or (+18 points) and the Nasdaq futures are UP +0.36% or (+77 points)

  • Stock futures were slightly higher Tuesday,
  • European markets crept higher,
  • Asia-Pacific markets fell while Australian stocks gained with Japan and South Korea’s stock markets closed

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Indexes moved lower Monday taking the cell and gene therapy sector with it.

  • Monday: The Dow closed DOWN -418.48 points or -0.97%, the S&P closed DOWN -63.90 points or -1.07% while the Nasdaq closed DOWN -235.25 points or -1.19%
  • Monday’s cell and gene therapy sector advance/decline line ended with a negative close at the close of 7 incliner, 27 decliners and 1 flat
  • The Nasdaq popped +7.1%, the S&P +2.5%, in Q4/24 and are both on pace for a 5th consecutive positive Q for the 1st time since 2021. The Dow is up +0.6% over the same period for its 4th positive Q in 5.

Economic Data Docket: nada

 

Q4/24: December = 1 holiday, 15 negative and 5 positive closes

  • November 10 negative and 9 positive closes
  • October: 8 positive and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context 

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

Alnylam Pharmaceuticals (ALNY) shows a pre-open positive of +$0.99 or +0.42%

Moderna (MRNA) shows a pre-open positive of +$0.35 or +0.89%

Beam therapeutics (BEAM) shows a pre-open positive of +$1.12 or +4.43%

BioLife Solutions (BLFS) shows a pre-open positive of +$0.60 or +2.28%

CRISPR Therapeutics (CRSP) shows a pre-open positive of +$0.37 or +0.96%

Vericel (VCEL) shows a pre-open positive of +$0.30 or +0.54%

uniQure NV (QURE) shows a pre-open positive of +$0.88 or +5.11%

 

Negative Indications:

Lenz Therapeutics (LENZ) shows a pre-open negative of -$2.05 or -6.82%

Sangamo Therapeutics (SGMO) shows a pre-open negative of -$1.20 or -51.28%

 

The BOTTOM LINE:  This is the end ... <from Jim Morrison>

  • Beautiful friend
  • This is the end
  • My only friend, the end
  • Of our elaborate plans, the end
  • Of everything that stands, the end
  • No safety or surprise, the end
  • I'll never look into your eyes again
  • Can you picture what will be?

 

There are clear winners with mostly losers in December … and 2024.

  • Think about it; the biggest problem the cell and gene therapy sector has …  99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject to debt servicing firms!

 

I seem to be asking a question followed by a question …

  • Do we need to brace ourself for more economics and their down trending affect?
  • Is this market STILL “bubblicious” my concerns are macroeconomic and valuation

 

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.